Fingerprint
Dive into the research topics of 'Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial
B. E. Elewski, C. S. Baker, J. J. Crowley, Y. Poulin, M. M. Okun, B. Calimlim, Z. Geng, O. Reyes Servin, P. A. Rich
Research output: Contribution to journal › Article › peer-review
24
Scopus
citations